Business Context and Reporting Period
Company: Quince Therapeutics, Inc. (QNCX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Quince is a late-stage biotechnology company focused on its proprietary AIDE technology platform, which encapsulates drugs into a patient's own red blood cells. The company's lead asset, eDSP, was in development for Ataxia-Telangiectasia (A-T).
Current Status: In January 2026, the company completed its pivotal Phase 3 NEAT clinical trial for eDSP. The trial failed to meet its primary and key secondary endpoints. Consequently, the company has ceased development of eDSP and has no other current product candidates. Management is currently evaluating strategic alternatives, including a potential reverse merger, to maximize shareholder value.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(84.0) million | $(56.8) million |
| Operating Expenses | $58.1 million | $57.3 million |
| Cash, Cash Equivalents & Short-Term Investments (Dec 31, 2025) | $17.8 million | $40.8 million |
| Accumulated Deficit (Dec 31, 2025) | $(460.5) million | $(376.5) million |
| Debt (EIB Loan Fair Value) | $18.0 million | $14.3 million |
| Contingent Consideration Liability | $64.3 million | $56.7 million |
| Warrant Liability | $32.2 million | $0 |
Note: The company has never generated revenue and has never been profitable.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by 48% to $84.0 million in 2025 compared to $56.8 million in 2024. This was driven primarily by a $21.5 million loss from the change in fair value of warrant liabilities and a $7.6 million increase in the fair value of contingent consideration.
- R&D Expenses: Research and development expenses increased by 90% to $35.4 million, primarily due to costs associated with the Phase 3 NEAT clinical trial ($27.6 million).
- Goodwill Impairment: Unlike 2024, which included a $17.1 million goodwill impairment charge, no goodwill impairment was recorded in 2025 (though subsequent events indicate expected impairment of In-Process Research and Development assets).
- Liquidity: Cash and short-term investments decreased significantly from $40.8 million in 2024 to $17.8 million in 2025 due to operating cash burn of $41.4 million.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategic Alternatives
Following the failure of the NEAT trial, the company has no product candidates and insufficient resources for further R&D. On February 9, 2026, the company engaged LifeSci Capital to evaluate strategic alternatives, with a focus on a reverse merger. The company intends to raise additional funding through public offerings (ATM program) or private financing to fund these activities.
Going Concern
The company has concluded that there is substantial doubt about its ability to continue as a going concern for one year following the issuance of the financial statements. Management believes current cash resources will fund operations only into the second quarter or second half of 2026, contingent on warrant exercises.
Unusual Items and Subsequent Events
- Warrant Liability: A $21.5 million non-cash loss was recorded in 2025 due to the fair value adjustment of warrants issued in a June 2025 private placement.
- Debt Settlement: In March 2026, the company settled its EIB Loan obligations in full with a payment of 4.8 million euros ($5.5 million).
- Contingent Consideration: As of March 2026, it was determined that criteria for the $64.3 million contingent consideration liability would not be met, resulting in the liability being reduced to zero.
- Reverse Stock Split: On April 2, 2026, the Board approved a 1-for-10 reverse stock split, effective April 10, 2026.
- Nasdaq Compliance: The company received notices in March 2026 regarding non-compliance with Nasdaq listing requirements (minimum bid price and market value of listed securities).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $17.8 million cash balance (plus subsequent ATM proceeds) to fund the strategic alternative process and debt settlement.
- Strategic Transaction Viability: Assess the likelihood and terms of the proposed reverse merger or other strategic alternatives given the lack of product candidates.
- Debt and Liability Resolution: Confirm the final settlement of the EIB Loan and the write-off of the contingent consideration liability as reported in subsequent events.
- Nasdaq Listing Status: Monitor the company's progress in regaining compliance with Nasdaq listing requirements to avoid delisting.
- Dilution Risk: Evaluate the impact of the 1-for-10 reverse stock split and potential future equity issuances on shareholder ownership.